PINK - ETF AI Analysis
Top Page
Simplify Health Care ETF (PINK)
Rating:65Neutral
Price Target:―
Positive Factors
Strong Leading Holdings
Several of the largest positions, such as Align Technology, United Therapeutics, Jazz Pharmaceuticals, and Warby Parker, have shown strong performance this year, helping support the fund despite broader weakness.
Focused Health Care Exposure
With most of its assets in health care companies, the ETF gives investors targeted access to a sector that can benefit from long-term trends like aging populations and medical innovation.
Meaningful Fund Size
The fund manages a sizable pool of assets, which can help support trading liquidity and ongoing fund operations.
Negative Factors
Recent Weak Overall Performance
The ETF has delivered weak returns so far this year and over the last three months, indicating recent performance headwinds.
Concentrated Sector Risk
With the vast majority of its holdings in health care, the fund is heavily exposed to sector-specific risks such as regulatory changes and drug-pricing pressures.
Mixed Top-Holding Results
Some major positions, including Novo Nordisk, Eli Lilly, AbbVie, and PureCycle Technologies, have lagged this year, which has weighed on the fund’s overall results.
PINK vs. SPDR S&P 500 ETF (SPY)
AUM273.35M
RegionNorth America
Expense Ratio0.51%
Beta0.69
IssuerSimplify
Inception DateOct 07, 2021
Dividend Yield0.67%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume75,336
30 Day Avg. Volume93,416
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
45.77Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering52
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PINK Summary
The Simplify Health Care ETF (PINK) focuses on the health care theme rather than tracking a specific index. It invests mainly in U.S. health care companies across areas like biotech, drug makers, medical devices, and health care services. Well-known holdings include Eli Lilly & Co and UnitedHealth, giving investors exposure to major players in medicine and insurance. Someone might invest in PINK to seek long-term growth from medical innovation and an aging population, while still getting a mix of different health care businesses. A key risk is that it is heavily concentrated in the health care sector, so its value can rise or fall sharply with that industry.
How much will it cost me?The Simplify Health Care ETF (PINK) has an expense ratio of 0.5%, which means you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specific sector like health care, which requires more research and expertise. It’s designed to give investors targeted exposure to innovative health care companies.
What would affect this ETF?The Simplify Health Care ETF (PINK) could benefit from advancements in biotechnology and pharmaceuticals, as well as increased demand for health care services driven by aging populations and global health awareness. However, it may face challenges from regulatory changes, pricing pressures in the pharmaceutical industry, and potential economic downturns that could impact consumer spending on health care. Its strong U.S. focus and top holdings in companies like UnitedHealth and AbbVie position it well for growth but also expose it to risks tied to U.S. health care policies.
PINK Top 10 Holdings
PINK is very much a health‑care story, with its biggest swings coming from a mix of high-growth biotech and steady blue-chip drugmakers, all rooted in the U.S. market. Jazz Pharmaceuticals and UnitedHealth have been rising and acting like key engines for the fund, while Novo Nordisk and AbbVie are more mixed, occasionally tapping the brakes. PureCycle, despite its promise, looks more like a wild card that can inject volatility rather than steady gains. Overall, the ETF leans into innovative, and sometimes bumpy, health‑care names.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| PureCycle Technologies | 10.38% | $28.35M | $2.26B | 26.67% | 38 Underperform | |
| United Therapeutics | 7.24% | $19.79M | $23.34B | 68.76% | 79 Outperform | |
| Novo Nordisk | 6.29% | $17.19M | $194.76B | -42.44% | 73 Outperform | |
| Eli Lilly & Co | 5.81% | $15.87M | $1.07T | 48.52% | 72 Outperform | |
| Johnson & Johnson | 5.20% | $14.20M | $560.33B | 49.56% | 78 Outperform | |
| UnitedHealth | 4.80% | $13.13M | $362.78B | 31.76% | 72 Outperform | |
| Jazz Pharmaceuticals | 4.75% | $12.97M | $14.97B | 107.42% | 64 Neutral | |
| AbbVie | 4.25% | $11.61M | $401.47B | 19.70% | 66 Neutral | |
| Align Tech | 4.20% | $11.47M | $12.01B | -4.91% | 74 Outperform | |
| Biohaven Ltd. | 3.73% | $10.19M | $1.63B | -36.58% | 40 Underperform |
PINK Technical Analysis
Positive
―
Price Trends
35.64
Positive
35.60
Positive
34.75
Positive
Market Momentum
0.61
Positive
55.54
Neutral
63.79
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PINK, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 37.07, equal to the 50-day MA of 35.64, and equal to the 200-day MA of 34.75, indicating a bullish trend. The MACD of 0.61 indicates Positive momentum. The RSI at 55.54 is Neutral, neither overbought nor oversold. The STOCH value of 63.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PINK.
PINK Peer Comparison
Comparison Results
Performance Comparison
PINK
Simplify Health Care ETF
37.35
8.04
27.43%
IETC
iShares Evolved US Technology ETF
―
―
―
GTOP
Goldman Sachs Technology Opportunities ETF
―
―
―
RSHO
Tema American Reshoring ETF
―
―
―
IYRI
NEOS Real Estate High Income ETF
―
―
―
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents